Get the app
US › Healthcare

Purple Biotech (PPBT)

US · Healthcare · Biotechnology

$1.14-7.32%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$441,000
EPS
$1.07
EPS estimate
$-0.98

EPS came in at 1.07 against a street estimate of -0.98 — a beat of 209.2%.

Key statistics

Market cap
$2.0M
Forward P/E
0.0
P/B
0.20
Book value
$12.00
EPS (TTM)
$-47.64
52-week high
$14.10
52-week low
$1.13
50-day MA
$1.57
200-day MA
$3.36
Beta
-0.55

Analyst view

Analysts rate Purple Biotech a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $17.00.

Shareholding

Institutions
10.83%

Largest institutional holders

FundStake
SmartHarvest Portfolios, LLC1.75%
HRT FINANCIAL LLC0.90%
Citadel Advisors Llc0.81%
Susquehanna International Group, LLP0.79%
Independent Advisor Alliance0.73%
SRS Capital Advisors Inc0.09%
Rhumbline Advisers0.05%
UBS Group AG0.05%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Purple Biotech — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.